Cargando…
PEGylated Protein Drugs: Basic Science and Clinical Applications
PEGylated Protein Drugs: Basic Science and Clinical Applications describes the basic technologies and the major results obtained with the PEGylation technique, the covalent binding to proteins, peptides and small organic molecules of the hydrophilic and biocompatible polymer poly(ethylene glycol) to...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Basel :
Birkhäuser Basel : Imprint: Birkhäuser,
2009.
|
| Edición: | 1st ed. 2009. |
| Colección: | Milestones in Drug Therapy,
|
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-7643-8679-5 | ||
| 003 | DE-He213 | ||
| 005 | 20220116111435.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 100301s2009 sz | s |||| 0|eng d | ||
| 020 | |a 9783764386795 |9 978-3-7643-8679-5 | ||
| 024 | 7 | |a 10.1007/978-3-7643-8679-5 |2 doi | |
| 050 | 4 | |a RM300-666 | |
| 072 | 7 | |a MMG |2 bicssc | |
| 072 | 7 | |a MED071000 |2 bisacsh | |
| 072 | 7 | |a MKG |2 thema | |
| 082 | 0 | 4 | |a 615 |2 23 |
| 245 | 1 | 0 | |a PEGylated Protein Drugs: Basic Science and Clinical Applications |h [electronic resource] / |c edited by Francesco M. Veronese. |
| 250 | |a 1st ed. 2009. | ||
| 264 | 1 | |a Basel : |b Birkhäuser Basel : |b Imprint: Birkhäuser, |c 2009. | |
| 300 | |a IX, 290 p. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Milestones in Drug Therapy, |x 2296-6064 | |
| 505 | 0 | |a Preface PEGylated protein conjugates: A new class of therapeutics for the 21st century -- Protein PEGylation, basic science and biological applications -- Reactive PEGs for protein conjugation -- Rebridging disulphides: site-specific PEGylation by sequential bis-alkylation -- Enzymatic techniques for PEGylation of biopharmaceuticals -- The site-specific TGase-mediated PEGylation of proteins occurs at flexible sites -- Protein conjugates purification and characterization -- PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals -- The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol) -- Pegfilgrastim - designing an improved form of rmetHuG-CSF -- PEGylation of human growth hormone: strategies and properties -- PEGylated ? interferons: two different strategies to achieve increased efficacy -- Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout -- Certolizumab pegol: a PEGylated anti-tumour necrosis factor alpha biological agent -- PEG: a useful technology in anticancer therapy -- Regulatory strategy and approval processes considered for PEG-drug conjugates and other nanomedicines. | |
| 520 | |a PEGylated Protein Drugs: Basic Science and Clinical Applications describes the basic technologies and the major results obtained with the PEGylation technique, the covalent binding to proteins, peptides and small organic molecules of the hydrophilic and biocompatible polymer poly(ethylene glycol) to improve their therapeutic efficacy. The book results from the collaboration of recognized experts from academia and industry, working on various aspects of the PEGylation technology. The first chapters provide general information on the physicochemical, pharmacokinetic, immunogenic and toxicological properties of PEG and PEG-conjugates. The classical and more advanced chemical strategies for linking PEG to protein drugs are described as well as novel enzyme-catalysed approaches. Further chapters are devoted to important PEGylated products, namely PEG conjugates of enzymes, cytokines, antibodies or synthetic organic molecules already on the market or in an advanced state of clinical experimentation. Guidelines for the approval by the Health Agencies of these new nanomedicines are also reported as a last chapter. Therefore, this book may be a unique instrument for a thorough review of the strategy, advantages and limitations of all aspects of drug PEGylation as well as a stimulation for researchers to develop new exploitations of this technology. It is of interest to physicians, biochemists, pharmacologists and chemists. | ||
| 650 | 0 | |a Pharmacology. | |
| 650 | 0 | |a Immunology. | |
| 650 | 0 | |a Biotechnology. | |
| 650 | 0 | |a Clinical biochemistry. | |
| 650 | 0 | |a Medicinal chemistry. | |
| 650 | 1 | 4 | |a Pharmacology. |
| 650 | 2 | 4 | |a Immunology. |
| 650 | 2 | 4 | |a Biotechnology. |
| 650 | 2 | 4 | |a Medical Biochemistry. |
| 650 | 2 | 4 | |a Medicinal Chemistry. |
| 700 | 1 | |a Veronese, Francesco M. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783764394943 |
| 776 | 0 | 8 | |i Printed edition: |z 9783764386788 |
| 830 | 0 | |a Milestones in Drug Therapy, |x 2296-6064 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-3-7643-8679-5 |z Texto Completo |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||